Your session is about to expire
← Back to Search
Triple Drug Combo for Solid Cancers
Study Summary
This trial will investigate the safety and effectiveness of a combination of drugs in treating multiple solid tumors.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I cannot swallow pills or have a digestive issue affecting drug absorption.I have a severe fistula in my GI tract or elsewhere.My liver is not working well.My esophageal cancer worsened after one standard treatment.I have a history of HIV infection.I am not pregnant or breastfeeding.I have not had any bleeding episodes in the last 3 months.I have not had chemotherapy for my liver cancer.I have a history of high-grade sarcomas.I have been diagnosed with an advanced solid tumor such as liver, colon, pancreas, bile duct, uterine, or esophageal cancer.I have had at least one treatment for bile tract cancer.I have another cancer that is getting worse.I need extra oxygen or my oxygen levels are below 92% when resting.My cancer has spread to my brain or the membranes around my brain and spinal cord.I haven't had serious heart problems in the last 6 months.My pleural effusion symptoms are stable after treatment.I have a serious wound or bone fracture that is not healing.I require dialysis.My organs are functioning well.I will follow the study's birth control advice.I have been treated with specific medications before.My blood pressure is under control.My scans show a hollow area or major blood vessel involvement in my tumor.I have lost more than 20% of my weight in the last 3 months or have fluid buildup in my abdomen or chest.My condition has worsened despite recent treatment.I have had at least 2 treatments for my colorectal cancer.I have had 1 or 2 treatments for pancreatic cancer.This is my first treatment for my condition, and I haven't had chemotherapy before.I have had Hepatitis B or currently have Hepatitis C.
- Group 1: Arm 2: Pembrolizumab + Lenvatinib
- Group 2: Arm 1: Pembrolizumab + Belzutifan + Lenvatinib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the estimated number of participants in this research undertaking?
"This research project will be conducted by Merck Sharp & Dohme LLC and necessitates 730 participants that meet the specified criteria. Two of their medical centres, Memorial Sloan Kettering Cancer Center (Site 5050) in New york, NY and City of Hope Comprehensive Cancer Center ( Site 5002) in Duarte, CA are expected to have a prominent role throughout the trial."
In what localities can participants access this research endeavor?
"The trial is available at 14 sites, including Memorial Sloan Kettering Cancer Center (Site 5050) in New york City, City of Hope Comprehensive Cancer Center (Site 5002) in Duarte CA, and Cedars-Sinai Medical Center ( Site 5045 )in Los Angeles. Additionally there are other locations offering the drug treatment."
What health conditions is Belzutifan most commonly employed to address?
"Belzutifan has been shown to be an effective treatment for patients with unresectable melanoma, microsatellite instability high conditions as well as those at risk of relapse."
Are there any openings still available for participation in this experiment?
"Affirmative. Clinicaltrials.gov data confirms that this medical trial, which was launched on August 18th 2021 is still actively recruiting patients from 14 different sites with a goal of 730 participants in total."
What safety considerations should be taken into account when utilizing Belzutifan?
"Despite being at Phase 2, our team believes that Belzutifan is reasonably safe and has thus assigned a score of 2. As the trial is still ongoing, clinical efficacy data remains unavailable."
Could you elaborate on the other empirical tests conducted with Belzutifan?
"Belzutifan was initially studied in 2010 by City of Hope. This has since been followed up with 303 completed studies, and there are currently 1042 ongoing clinical trials primarily operating from New york City."
What is the objective of this clinical research effort?
"Merck Sharp & Dohme LLC, the founder of this trial, reports that its primary objective is to measure adverse events in participants over a period of 21 days. Additionally, other secondary outcomes include progression-free survival per RECIST 1.1 and best overall response (CR/PR/SD) after 6 weeks measured by BICR as well as participant Adverse Events when treated with pembrolizumab plus lenvatinib."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger